Description
Created On: 2020-07-15
Record Count: 9
Primary Industries
- Cancer
- Drugs
- Therapeutic
- Medical
- Diagnostic
- Disease
- HIV / AIDs
- cell therapy
- Pharmaceuticals
- Device
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 230821
* Is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Product is made, used, or sold;
* Is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which the Licensed Product is used or sold.
A Licensed Process shall mean any process with application solely in the Non-Thalidomide Field and which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights.
Thalidomide may have use in treating diseases fed by the growth of tiny blood vessels – a growth process known as angiogenesis.
Licensee licensed the use of Thalidomide for cancer and other antiangiogenic mediated diseases from Licensor, and conducted four Phase II clinical trials and secured two orphan drug indications for the use of thalidomide in certain cancers.
IPSCIO Record ID: 203418
The term product shall mean any article of manufacture, substance, material, chemical, formulation or composition for use in the Field which is or includes Thalidomide as an active ingredient, including, without limitation, a composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s). The Product expressly excludes Thalidomide analogs.
THALOMID(R) (thalidomide), Licensee's lead product is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers.
Erythema nodosum leprosum is one of the most frequently used terms in the science of leprosy. It is an immune-mediated complication of leprosy presenting with inflammatory skin nodules. Immune complex production and deposition as well as complement activation have long been regarded as the principal etiology of ENL. ENL is characterised by an inflammatory infiltrate of neutrophils with vasculitis. There is deposition of immune complexes and complement together with Mycobacterium leprae antigens in the skin.
IPSCIO Record ID: 286016
US Patent #5,200,553 – Biologically active carboxylic acid esters
Licensed Product(s) shall mean: Any product which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the product is made, used, leased, or sold; Any product which is manufactured by using a process which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the process is used; Any product which is used according to a method which is covered in whole or in part by a valid and unexpired claim contained in the Patent Rights in the country in which the method is used.
Licensed Process(es) shall mean any process or method, which is covered, in whole or in part, by a valid and unexpired claim contained in the Patent Rights in the country in which the process or method is used.
IPSCIO Record ID: 203485
Licensor agrees that it shall not grant any other license to make, have made, use, lease and sell Licensed Products or to utilize Licensed Processes in the Research or In Vitro Diagnostics fields and in the In Vivo Diagnostics field and the Therapeutics field of use during the period.
At the end of the exclusivity period, the Licensee may extend the exclusivity or the rights will change to non-exclusive for the remainder of the term of the agreement.
Licensor agrees that its grant to Licensee to use of the Tangible Property for commercial purposes shall be exclusive in perpetuity unless this Agreement is terminated prior to the last to expire of the Patent Rights.
The Tangible Property shall mean any or all of the hybridorna cell lines from the Licensors laboratory with the designation(s) MCF-7 Bl through B9.
A Licensed Product shall mean any product or part thereof which:
(a) is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Product is made, used or sold; or, a valid and unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Product is made, used or sold; or
(b) is manufactured using a process which is covered in whole or in part by a pending claim contained in a Patent Rights Patent Application in the country in which any Licensed Process is used, or, a valid or unexpired claim contained in a Patent Rights Patent in the country in which any Licensed Process is used; or,
(c) is developed or manufactured using the Tangible Property.
A Licensed Process shall mean any process for making Licensed Products which is covered in whole or in part by:
(a) a pending claim contained in a Patent Rights Patent Application; or
(b) a valid and unexpired claim contained in a Patent Rights Patent; or which
(c) uses the Tangible Property.
The Licensee develops, produces and distributes products for the diagnosis and potential treatment of cancer based on its proprietary nuclear matrix protein technology.
IPSCIO Record ID: 230759
A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.
A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or, is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].
(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].
c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].
(d) All human [infectious diseases other than HIV]. This Field includes: [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.
IPSCIO Record ID: 233463
Angiogenesis is the biological process by which new blood vessels are formed and primarily occurs during the first three months of embryonic development.
The Licensee is currently developing two endogenous proteins, Angiostatin(TM) and Endostatin(TM), as potential long term cancer therapeutics to prevent metastatic disease and as therapies for primary tumors. These two proteins are different in structure and origin but have similar activity.
IPSCIO Record ID: 26020
Thalidomide means the chemical described as 2-(2,6- Dioxo-3-piperidinyl)-lH- isoindole-1,3(2H)-dione
Thalidomide Analog means and includes any and all analogs, metabolites, precursors, and hydrolysis products of Thalidomide, and all stereoisomers of each of the foregoing, including without limitation (a) all such compounds disclosed, generically or specifically, or claimed by any of the Analog Patents, (b) Amino Thalidomide and all stereoisomers and metabolites thereof; and (c) Revimid, and all stereoisomers and metabolites thereof.
Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of erythema nodosum leprosum (ENL; episodes of skin sores, fever, and nerve damage that occur in people with Hansen's disease [leprosy]). Thalidomide is in a class of medications called immunomodulatory agents. It treats multiple myeloma by strengthening the immune system to fight cancer cells. It treats ENL by blocking the action of certain natural substances that cause swelling.
IPSCIO Record ID: 227272
This agreement also contains a non-exclusive grant back from Licensee to Licensor.
Technology relates to angiogenesis, including anti-angiogenic diagnostic applications.
Angiogenesis means the growth of new blood vessels. Anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels. If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it.
Licensee is engaged in research and development of biotechnology and pharmaceutical products which regulate the growth of new blood vessels.
IPSCIO Record ID: 289227
In consideration of the royalties, and subject to the terms and conditions, as set forth in this Agreement and effective upon the earlier to occur of (i) written notification to University during the option period that Licensee desires to license the Patent(s), or (ii) expiration of the option period with no written notification given, University hereby grants to Licensee: i. the exclusive worldwide license in the field of use to use the Patent to make, have made, use distribute, and sell the Product(s); and ii. the right to grant sublicenses to any Patent licensed hereunder, provided that any sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to sublicensees.
USC#2860, filing date 12/15/1999
Product or Products shall mean any article, composition, apparatus, substance, chemical, material, method or service which is made, used, distributed or sold by Licensee which:
i. is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which the Product(s) is made, used, distributed or sold;
ii. is manufactured using a method or process which is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which (a) the Product(s) is made, use, distributed or sold, or (b) the method or process is used or sold;
iii. the use of which is covered in whole or in part by one or more pending or unexpired claims contained in a Patent in the country in which (a) the Product(s) is made, used, distributed or sold, or (b) the method or process is used or sold; or
iv. incorporates Information transferred to Licensee pursuant to the confidential disclosure agreement dated January 7, 2000 between University and Licensee (as the term Information is defined in said agreement).
